Physician profile
Kyleen E Davis
NPI 1053644062
$6,468.40
in general payments reported to CMS, 2019-2025
34 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $822 · 2022: $815 · 2023: $1,148 · 2024: $1,575 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Education: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.40 |
| Education | $395.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,088.20 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $683.47 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $459.55 | 2021-2025 | |
| Pfizer INC. | $425.20 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $420.49 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $319.26 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $310.37 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Incyte Corporation | $306.44 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $259.67 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $259.63 | 2023-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $255.18 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.91 | 2022-2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $239.53 | 2024-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $125.98 | 2021-2025 | Cabtreo, Jublia, Arazlo |
| Almirall LLC | $119.06 | 2021-2023 | Seysara |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $116.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $110.17 | 2024-2025 | |
| Dermavant Sciences, INC. | $101.18 | 2023-2024 | Vtama |
| Convatec INC. | $77.40 | 2023-2025 | |
| Revance Therapeutics, INC. | $74.50 | 2024 | Daxxify |
| Leo Pharma INC. | $73.39 | 2021-2025 | Anzupgo |
| Organogenesis INC. | $45.67 | 2021-2024 | Puraply Am |
| Ucb, INC. | $43.67 | 2022-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $43.64 | 2021 | |
| Biofrontera INC. | $42.04 | 2025 | |
| Genentech USA, INC. | $40.94 | 2023-2024 | Erivedge |
| Kerecis Limited | $28.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Botanix Sb INC | $26.20 | 2025 | Sofdra |
| Organon LLC | $25.32 | 2025 | |
| Mission Pharmacal Company | $23.25 | 2022 | |
| Biowound Solutions, INC. | $21.22 | 2025 | Bio-Connekt |
| Krystal Biotech INC | $20.18 | 2024 | Vyjuvek |
| Dermira, INC. | $18.38 | 2021 | |
| Smith+Nephew, INC. | $15.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyleen Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.